Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC and FANCA-deficient mononuclear phagocytes
Praveen Anur; Jane Yates; Michael R. Garbati; Scott Vanderwerf; Winifred Keeble; Keaney Rathbun; Laura E. Hays; Jeffrey W. Tyner; Johanna Svahn; Enrico Cappelli; et al. (Profiled Authors: Grover Bagby; Laura Hays; Jeffrey Tyner)
Fanconi anemia, complementation group C (FANCC)-deficient hematopoietic stem and progenitor cells are hypersensitive to a variety of inhibitory cytokines, one of which, TNFα, can induce BM failure and clonal evolution in Fancc-deficient mice. FANCC-deficient macrophages are also hypersensitive to TLR activation and produce TNFα in an unrestrained fashion. Reasoning that suppression of inhibitory cytokine production might enhance hematopoiesis, we screened small molecules using TLR agonist-stimulated FANCC-and Fanconi anemia, complementation group A (FANCA)-deficient macrophages containing an NF-κB/AP-1-responsive reporter gene (SEAP). Of the 75 small molecules screened, the p38 MAPK inhibitor BIRB 796 and dasatinib potently suppressed TLR8-dependent expression of the reporter gene. Fanconi anemia (FA) macrophages were hypersensitive to the TLR7/8 activator R848, overproducing SEAP and TNFα in response to all doses of the agonist. Low doses (50nM) of both agents inhibited p38 MAPK-dependent activation of MAPKAPK2 (MK2) and suppressed MK2-dependent TNFα production without substantially influencing TNFα gene transcription. Overproduction of TNFα by primary FA cells was likewise suppressed by these agents and involved inhibition of MK2 activation. Because MK2 is also known to influence production and/or sensitivity to 2 other suppressive factors (MIP-1α and IFNγ) to which FA hematopoietic progenitor cells are uniquely vulnerable, targeting of p38 MAPK in FA hematopoietic cells is a rational objective for preclinical evaluation. © 2012 by The American Society of Hematology.
PMID: 22234699 PMCID: PMC3311243
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Amy M. Skinner; S. Lee O'Neill; Markus Grompe; Peter KurreExperimental Hematology. 2008;36(3):273-282.
Tetsuya Otsuki; Shoichi Nagakura; Jianxiang Wang; Michael Bloom; Markus Grompe; Johnson M. LiuJournal of Cellular Physiology. 1999;179(1):79-86.
Francesco Galimi; Meenakshi Noll; Yoshiyuki Kanazawa; Timothy Lax; Cindy Chen; Markus Grompe; Inder M. VermaBlood. 2002;100(8):2732-2736.
Appears in this Document